atomoxetine / Generic mfg. - LARVOL DELTA

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - P4 | N=396 | Completed | Sponsor: Shire | Active, not recruiting ➔ Completed

Trial completion • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Acetazolamide plus Atomoxetine Changed Chemosensitivity in Obesity Hypoventilation Syndrome (ERS 2025) - No abstract available

Genetic Disorders • Obesity • Respiratory Diseases

Differential effects of drugs for Insomnia and Sleep apnea : A Focus on sleep macrostructure and microstructure in rat (WSS 2025) - "Atomoxetine and acetazolamide were assessed as drugs studied for SAS. Both lemborexant and trazodone modulate sleep, but their effects on sleep macrostructure and microstructure differ. Given that these drugs have different mechanisms of action, their distinct effects on sleep macrostructure and microstructure may suggest that each is suited to different types of sleep disorders. While macrostructural changes are considered important for insomnia, microstructural aspects may also play a meaningful role."

Preclinical • CNS Disorders • Insomnia • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Investigating the therapeutic role of atomoxetine in ministration of rheumatoid arthritis pain (NeuPSIG 2025) - "This study aims to develop a preclinical model of RA pain and evaluate the analgesic effects of atomoxetine in mitigating pain behaviors in CFA-induced RA pain models.Animals-Male Sprague Dawley rats (wt-200-220 gm)Drugs- Atomoxetine (Dose:2mg/kg,5mg/kg,10mg/kg), Indomethacin (5mg/kg)Animal Model: CFA-induced Rheumatoid ArthritisBehavior essays• Von-Frey test: Mechanical allodynia• Pin-prick test: Mechanical Hyperalgesia• Hargreaves test: Thermal Hyperalgesia• Acetone Drop test: Cold allodynia• Ice-floor test: Cold Hyperalgesia• Ongoing Pain: Conditioned Placed Preference• CNS toxicity: Rotarod test, open field test• Biochemical tests-GSH(Glutathione), nitrite, MDA(Malondialdehyde)• Molecular tests-rt-PCR, Western Blotting Atomoxetine significantly reduced CFA-induced mechanical allodynia, thermal hyperalgesia, and cold allodynia in a dose-dependent manner. This study provides preclinical evidence that atomoxetine effectively mitigates RA-associated pain by modulating..."

Addiction (Opioid and Alcohol) • CNS Disorders • Musculoskeletal Pain • Pain • TNFA • TRPA1

Development of a Sensitive Fluorimetric Method for Atomoxetine Determination in Tablets and Plasma Using a Dansyl Chloride Derivatization Approach. (PubMed, Luminescence) - "The % Recovery ± SD of the proposed and reported methods was similar, with t-values (0.27-0.76) and F-values (1.37-3.17), confirming the method's reliability and consistency. Sustainability profiling using the RGB12 algorithm, Green Certificate, AGREE, SPMS, and BAGI tools showed a good sustainability profile."

Journal • Multiple Sclerosis

Need for combined therapy for a rare case of autoimmune autonomic ganglionopathy: A case report. (PubMed, World J Methodol) - "Our case report supports the benefit of combined immunomodulatory therapy for refractory AAG cases that are unresponsive to single-agent treatment."

Journal • Constipation • Erectile Dysfunction • Gastroenterology • Gastrointestinal Disorder • Hypotension • Immunology • Xerostomia

Catecholamines reduce choice history biases in perceptual decision making. (PubMed, PLoS Biol) - "Atomoxetine and variations of pupil-linked arousal at slower and faster timescales had analogous effects on choice history bias. We conclude that catecholamines reduce the impact of a specific form of prior on perceptual decisions."

Journal

An Updated Network Meta-Analysis of Pharmacological Therapies for Obstructive Sleep Apnea: Effects on AHI Reduction and Lowest Oxygen Saturation Improvement (WSS 2025) - "For AHI reduction, 80 mg atomoxetine combined with 5 mg oxybutynin demonstrated the most pronounced effect (MD –17.03 events/hour; 95% CI –23.63 to –10.43), followed by 80 mg atomoxetine plus 50 mg trazodone (MD –14.40; 95% CI –24.94 to –3.86) and 100 mg trazodone monotherapy (MD –13.70; 95% CI –22.19 to –5.21). Selected pharmacologic treatments, particularly atomoxetine-based combinations, significantly reduced AHI, while reboxetine improved SpO₂ nadir. These agents may offer alternative options for patients intolerant to CPAP, though further studies are needed to confirm their efficacy and safety."

Retrospective data • CNS Disorders • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Pharmacological and pupillary evidence for the noradrenergic contribution to reinforcement learning in Parkinson's disease. (PubMed, Commun Biol) - "Using a single dose of the noradrenaline reuptake inhibitor atomoxetine in people with Parkinson's disease (in a randomised double-blind placebo-controlled crossover design), we show improvements in learning compared to placebo...Our findings confirm the noradrenergic contribution to reinforcement learning, and in doing so they challenge the simple interpretation of tonic-phasic locus coeruleus firing patterns based on pupillometry. Noradrenergic modulation is a potential treatment strategy for cognitive symptoms in Parkinson's disease and related disorders."

Journal • CNS Disorders • Cognitive Disorders • Movement Disorders • Parkinson's Disease

Effectiveness of Atomoxetine Augmentation in Reducing Nonsuicidal Self-Injury Among Adolescents with Attention Problems: A Preliminary Study. (PubMed, J Child Adolesc Psychopharmacol) - "The subclinical ADHD group showed significant improvement in CDRS (p = 0.006), with a trend toward improvement in NSSI severity (p = 0.083). Atomoxetine augmentation may reduce NSSI severity in adolescents with attention problems, particularly in those with comorbid ADHD, warranting further investigation in larger controlled trials."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Mental Retardation • Psychiatry • Schizophrenia

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - P4 | N=397 | Active, not recruiting | Sponsor: Shire | N=288 ➔ 397 | Trial completion date: Jun 2027 ➔ Aug 2025 | Trial primary completion date: Jun 2027 ➔ Aug 2025

Enrollment change • Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Drugs for ADHD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Training Schedule Affects Operant Responding Independent of Motivation in the Neuroligin-3 R451C Mouse Model of Autism. (PubMed, Genes Brain Behav) - "The NL3 mouse model therefore likely best represents autistic individuals with intact non-social motivation but altered behavioural updating. Finally, we discuss the benefits and limitations of using heterogenous experimental designs to probe behavioural phenotypes and offer some general recommendations for PR."

Journal • Preclinical • Autism Spectrum Disorder • Genetic Disorders

Updated insights on memory disorder associated risk of medication: A real-world pharmacovigilance analysis. (PubMed, J Affect Disord) - "This study presents a comprehensive overview of medications that induce memory disorder from a pharmacovigilance perspective, may offering certain references for clinical practice. However, further research is required necessary to elucidate these associations."

Adverse events • Journal • Real-world evidence • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Pain

Transcranial Direct Current Stimulation Combined with Atomoxetine Hydrochloride in the Comprehensive Treatment of Attention Deficit Hyperactivity Disorder: A Clinical Study (ChiCTR) - P=N/A | N=80 | Recruiting | Sponsor: Children's Hospital Affiliated to Chongqing Medical University; Children's Hospital Affiliated to Chongqing Medical University

New trial • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Sporadic Dup15q Syndrome Presenting With Developmental Delay, Intellectual Disability, Attention-Deficit/Hyperactivity Disorder, and Epilepsy: A Case Report. (PubMed, Cureus) - "However, escitalopram triggered episodes of severe tantrums and was subsequently discontinued. This case highlights that Dup15q syndrome associated with a 300 kb microduplication can predominantly affect the central nervous system and may respond favorably to atomoxetine, methylphenidate, risperidone, and VPA. Dup15q syndrome should be considered in the differential diagnosis of individuals presenting with developmental delay, intellectual disability, ADHD, and epilepsy."

Journal • Absence Seizure Disorder • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Epilepsy • Genetic Disorders • Mental Retardation • Ophthalmology • Psychiatry • Strabismus

Noradrenaline for progressive supranuclear palsy syndromes (NORAPS): a randomised, double-blind, placebo-controlled, crossover Phase IIb clinical trial evaluating the efficacy and safety of oral atomoxetine for treating cognitive and behavioural changes in people with progressive supranuclear palsy syndromes in the UK. (PubMed, BMJ Open) - "Dissemination will include publication in peer-reviewed journals, presentations at academic and public conferences and engagement with patients, the public, policymakers and practitioners. ISRCTN99462035; DOI: https://doi.org/10.1186/ISRCTN99462035; EudraCT (European Union Drug Regulating Authorities Clinical Trials Database)/CTIS (Clinical Trial Information System) number: 2019-004472-19; IRAS (Integrated Research Application System) number: 272063; Secondary identifying numbers: CPMS (Central Portfolio Management System) 44441."

Clinical protocol • Journal • P2b data • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy

Unanticipated Pathological Laughter Following Atomoxetine Administration in a Child With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. (PubMed, Neuropsychopharmacol Rep) - "This case suggests that pathological laughter may be a rare but temporary side effect of atomoxetine, even at low doses. Given the child's familial history of bipolar disorder and the influence of catecholamines on mood regulation, clinicians should be vigilant in monitoring mood-related side effects in children with neurodevelopmental disorders. This report emphasizes the need for personalized treatment approaches and further investigation into the mechanisms and risk factors underlying this phenomenon."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • Bipolar Disorder • CNS Disorders • Developmental Disorders • Genetic Disorders • Mood Disorders • Pediatrics • Psychiatry

Compulsive coping behaviour, developed predominantly by sign-trackers, is exacerbated by chronic atomoxetine. (PubMed, Biol Psychiatry) - "These results provide new insight into the biobehavioural basis of compulsive behaviours, revealing a differential noradrenergic control of the development and expression of compulsive coping, the latter involving recruitment of distinct striatal processes."

Journal • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • EGR1 • FOS

A retrospective single-center study on the characteristics of children with attention-deficit hyperactivity disorder requiring early drug therapy from 2013 to 2022 and changes in treatment over time. (PubMed, Fukushima J Med Sci) - "These results suggest that characteristics of patients requiring early ADHD drug medication include age 6 years or older at first examination and high ADHD-RS-H, ADHD-RS-T and TS. Furthermore, an increase in the frequency of prescriptions for guanfacine was observed as a prescription trend for ADHD medications."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Attention-Deficit/Hyperactivity Disorder Subtypes Defined by Cognition Have a Distinct Neural and Clinical Profile and Differ in Response to Atomoxetine. (PubMed, J Am Acad Child Adolesc Psychiatry) - "Cognitive performance appears effective for identifying ADHD subtypes that have a distinct neural basis and that may particularly benefit from non-stimulants such as atomoxetine."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Mood Disorders • Psychiatry

Neuromodulatory influences on propagation of traveling waves along the unimodal-transmodal gradient. (PubMed, Cereb Cortex) - "Atomoxetine, which increases extracellular catecholamine levels, was associated with faster traveling waves, and faster traveling waves correlated with more network integration. We also examined temporal variations in pupil size, a signature of transient changes in neuromodulatory activity, and found that the periods of traveling waves were characterized by larger pupil size. Our results suggest that neuromodulatory tone affects traveling wave propagation, and that this arousal-modulated propagation shapes integrated functional connectivity features, highlighting specific effects of prolonged and transient neuromodulatory influences on slow brain dynamics."

Journal

The Evidence for Treatments for Postural Orthostatic Tachycardia Syndrome: A Systematic Review of Randomized Trials. (PubMed, Trends Cardiovasc Med) - "This review summarizes the available evidence from trials on propranolol, midodrine, pyridostigmine and ivabradine as well as less commonly used medications such as desmopressin, melatonin, atomoxetine, modafinil, sertraline and intravenous immunoglobulins. We conclude that many small trials have evaluated different treatments for POTS. Large randomized trials are needed to determine if mainstay treatments beta-blockers, midodrine, and pyridostigmine should be used as first line treatment(s)."

Clinical • Journal • Review • Cardiovascular • Hypotension

Attention-deficit hyperactivity disorder drug search trends: a Scandinavian perspective. (PubMed, Acta Neuropsychiatr) - "Furthermore, interest in lisdexamphetamine, relative to dextroamphetamine and atomoxetine, has increased sharply in recent years in the Scandinavian countries. Overall, internet search trends for ADHD drugs mirror reported prescription patterns and identify a dominance of methylphenidate, with an increasing interest in lisdexamphetamine. As such, search trends may serve as a feasible source for identifying geographical drug preferences."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Adaptive arousal regulation: Pharmacologically shifting the peak of the Yerkes-Dodson curve by catecholaminergic enhancement of arousal. (PubMed, Proc Natl Acad Sci U S A) - "The catecholaminergic agent atomoxetine increased overall arousal and shifted the entire arousal-performance curve, suggesting a relative arousal mechanism where performance adapts to arousal fluctuations within arousal states. In contrast, the cholinergic agent donepezil did not measurably affect arousal or the curve. We modeled these findings in a neurobiologically plausible computational framework, showing how catecholaminergic modulation alters a disinhibitory neural circuit that encodes sensory evidence for decision-making. This work suggests that performance adapts flexibly to arousal fluctuations, ensuring optimal performance in each and every global arousal state."

Journal